Leveraging Perioperative Cytokine Profiling to Reduce Acute Kidney Injury Risk

Clinical Insights from Trauma Preconditioning and the Role of Advanced Multiplex Biomarker Analysis.

 

 

Acute kidney injury (AKI) remains a major and costly complication of major surgery, associated with increased morbidity, mortality, and progression to chronic kidney disease. Traditional risk assessment based on clinical parameters often fails to capture early biological changes preceding renal dysfunction.

 

Recent research by McBride et al. (2026) demonstrates that perioperative cytokine profiling, particularly when analysed using integrated biomarker ratios, provides valuable insight into renal risk and immune response dynamics. This study compared elective cardiac surgery patients with orthopaedic trauma patients and revealed that trauma‑induced immune preconditioning results in temporarily reno‑protective cytokine profiles.

 

This manuscript summarises the study’s findings and highlights how Randox multiplex biomarker technologies enable actionable, scalable, and clinically meaningful cytokine profiling to support earlier AKI risk identification and improved perioperative decision‑making.

 

 

The Clinical Challenge: Acute Kidney Injury in Surgery

 

AKI affects a significant proportion of surgical patients, particularly those undergoing cardiac and emergency orthopaedic procedures. Patients who develop AKI experience:

 

• Longer hospital stays
• Increased need for intensive care
• Higher risk of long‑term renal impairment
• Increased mortality

 

Despite advances in perioperative care, AKI is often diagnosed after injury has occurred, when preventative options are limited.

 

There is a clear unmet need for diagnostics that detect biological vulnerability, not just physiological decline.

 

 

Beyond Single Biomarkers: The Case for Cytokine Profiling

 

Inflammation, hypoperfusion, and ischaemia–reperfusion injury play central roles in AKI pathogenesis. These processes are mediated by complex interactions between:

 

• Pro‑inflammatory cytokines
• Anti‑inflammatory counter‑regulatory responses
• Renal filtration and tubular exposure

 

The McBride et al. study illustrates that single biomarkers alone are insufficient. Instead, patterns and ratios of biomarkers across blood and urine more accurately reflect renal risk and resilience.

 

This approach requires:

 

• Simultaneous measurement of large biomarker panels
• High analytical precision
• Cross‑sample integration (blood + urine)

 

These requirements are met by Randox multiplex biochip technology.

 

The study, focuses on the retrospective analysis of two surgical cohorts:

 

• Elective cardiac surgery (n=401)
• Orthopaedic fracture (trauma) surgery (n=237)
• Measurement of 34 blood and urine biomarkers pre‑ and post‑operatively
• Biomarkers included inflammatory, anti‑inflammatory, hypoperfusion, and ischaemia–reperfusion indicators
• Calculation of renally favourable cytokine ratios (R1–R4)

 

All biomarker analyses were performed by Randox Clinical Laboratory Services, using ISO‑accredited multiplex testing platforms

 

 

Study Findings

 

 

Trauma Preconditioning Creates a Reno‑Protective Baseline

 

Orthopaedic trauma patients showed:

 

• Significantly higher pre‑operative pro‑ and anti‑inflammatory cytokine levels
• Higher renally favourable cytokine ratios prior to surgery

 

This suggests that trauma activates a balanced immune response that temporarily protects renal function.

 

 

Post‑Operative Cytokine Balance Influences Renal Risk

 

Post‑operatively:

 

• Cardiac surgery patients exhibited stronger urinary anti‑inflammatory responses
• Orthopaedic patients showed higher blood inflammation but comparatively lower urinary anti‑inflammatory excretion

 

This difference reflects the impact of haemodynamic control and renal filtration dynamics factors that standard monitoring may overlook without biomarker insight.

 

 

Cytokine Ratios Outperform Individual Biomarkers

 

Across both cohorts:

 

• Ratios combining urinary anti‑inflammatory markers with blood pro‑injury markers were most strongly associated with renal protection
• These ratios changed dynamically across the perioperative period

 

This confirms that integrated biomarker models, rather than isolated results, provide superior clinical insight.

 

 

The Randox Advantage – Comprehensive Multiplex Measurement

 

Randox platforms enable simultaneous quantification of cytokines, renal stress markers, hypoperfusion and IRI biomarkers to assess entire inflammatory pathways, not fragments.

 

 

Clinically Meaningful Ratio‑Based Analytics – The study validates Randox’s approach of translating raw biomarker data into:

 

• Renally protective vs injurious profiles
• Risk stratification tools for AKI

 

This elevates diagnostics from data generation to clinical decision support.

 

 

Robustness across surgical settings – Despite major differences between trauma and elective surgery patients:

 

• Many Randox‑measured biomarkers retained predictive relevance
• Algorithms remained applicable across specialties

 

This demonstrates scalability and versatility, essential for health systems adopting standardised perioperative risk tools.

 

 

Enabling Future Preventative Strategies – Study findings open the door to:

 

• Pharmacological cytokine preconditioning
• Earlier intervention in high‑risk patients
• Personalised perioperative care pathways

 

 

Clinical and Health System Impact – Workflow Improvements

 

By integrating cytokine profiling into surgical workflows, healthcare providers may:

 

• Identify AKI risk before creatinine rises
• Optimise haemodynamic and inflammatory management
• Reduce AKI incidence and downstream costs
• Improve patient outcomes and recovery trajectories